Gubra

610 DKK

-0.97 %

GUBRA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

26 following

-0.97%

+27.62%

+42.52%

-1.61%

+101.99%

+388%

+413.47%

+454.55%

investors.gubra.dk/overview/default.aspx

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.

Revenue

205.01M

EBIT %

-23.25 %

P/E

Dividend yield-%

Target price

Recommendation

Updated

NASDAQ Copenhagen

GUBRA

Daily low / high price

602 / 620 DKK

Market cap

9.97B DKK

Turnover

9.91M DKK

Volume

16K

Latest research

Gubra (One pager): Obesity Market Upgrade Enhances DCF Estimates

09.09.2024

Latest videos

Gubra – Presentation of Q3 2024

07.11.2024

Gubra: Stærk vækst i det underliggende fedmemarked, medfører et løft af vores estimater

19.09.2024

Gubra - Presentation of Q2 report 2024

23.08.2024

Financial calendar

Annual report

28.02.2025

Major Owners
Source: Millistream Market Data AB

Owner	Capital	Votes
Niels Vrang	30.6 %	30.6 %
Jacob Jelsing	27.5 %	27.5 %
Arbejdsmarkedets Tillægspension (ATP)	7.6 %	7.6 %
Capital Group	6.3 %	6.3 %
Henrik Blou with companies	3.2 %	3.2 %
Novi Investeringsanpartsselskab	2.2 %	2.2 %
Danica Pension	2.1 %	2.1 %
Knud Jørgen Jensen	1.4 %	1.4 %
Danske Invest	0.9 %	0.9 %
Industriens Pension	0.7 %	0.7 %

ShowingAll content types

Regulatory press release11/13/2024, 5:36 PM

Gubra announces positive GUBamy Phase 1 SAD data (correction)

Gubra

Regulatory press release11/13/2024, 4:41 PM

Gubra announces positive GUBamy Phase 1 SAD data

Gubra

Analyst Comment11/8/2024, 9:46 AM by

Claus Thestrup

Gubra: Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Gubra

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Webcast11/7/2024, 11:00 AM by

Claus Thestrup

Gubra – Presentation of Q3 2024

Meet and ask questions to Gubra’s management – CEO Henrik Blou and CFO Kristian Borbos on 7 November at 12.00 AM when they present the Q3 report 2024. Focus will be on Q3 report and the underlying growth in the CRO business area. Besides that, we expect an update on potential triggers in the D&P pipeline.

Gubra

Analyst Comment11/7/2024, 8:22 AM

Dagens aktienyheder 07/11: TORM, Gubra, Asetek, Ascelia Pharma, WindowMaster og Columbus

Dagens aktienyheder med TORM, Gubra, Asetek, Ascelia Pharma, WindowMaster og Columbus

WindowMaster International Columbus Torm Gubra Ascelia Pharma Asetek

Gubra: Another strong quarter in CRO and pipeline update

Analyst Comment11/7/2024, 8:04 AM by

Claus Thestrup

Gubra: Another strong quarter in CRO and pipeline update

Today, Gubra reported its Q3 2024 results. The company saw another strong quarter in the CRO business, driven by obesity service which is a major topic for the biotech and pharma industry.Read more here.

Gubra

Regulatory press release11/7/2024, 6:30 AM

Trading statement Q3-2024: Another strong quarter

Gubra

Analyst Comment11/1/2024, 8:13 AM

Dagens aktienyheder 1/11: Føroya Banki, Gubra, GomSpace og Aktier med Friis

Dagens aktienyheder med Føroya Banki, Gubra, GomSpace og Aktier med Friis

Føroya Banki GomSpace Group Gubra

Gubra: Shares drop 4% yesterday amid pipeline news, despite the news relating to a smaller part of our pipeline valuation

Analyst Comment10/31/2024, 1:04 PM by

Claus Thestrup

Gubra: Shares drop 4% yesterday amid pipeline news, despite the news relating to a smaller part of our pipeline valuation

Boehringer Ingelheim, Gubra's partner in multiple obesity projects, has decided to discontinue the clinical obesity project NYP2.

Gubra

Regulatory press release10/31/2024, 10:07 AM

Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim

Gubra

Analyst Comment10/3/2024, 7:12 AM by

Claus Thestrup, Rasmus Køjborg

Dagens aktienyheder 03/10: Curasight, Gubra, Skjern Bank og bankerne generelt

Dagens aktienyheder med Curasight, Gubra, Skjern Bank og bankerne generelt

Curasight Gubra Skjern Bank Vestjysk Bank Spar Nord Bank Danske Bank Grønlandsbanken Føroya Banki Sparekassen Sjælland-Fyn

Analyst Comment9/27/2024, 7:05 AM

Dagens aktienyheder 27/09: Netcompany, Life Sciences selskaber og Aktier med Friis

Dagens aktienyheder med Netcompany, Life Sciences selskaber og Aktier med Friis

Netcompany Group Gubra BioPorto Ascelia Pharma Pharma Equity Group ExpreS2ion Biotech Holding

Analyst Comment9/20/2024, 7:10 AM

Dagens aktienyheder 20/09: Columbus, Gabriel, Flügger og Gubra

Dagens aktienyheder med Columbus, Gabriel, Flügger og Gubra

Columbus Gabriel Holding Gubra Flügger Group

Gubra: Stærk vækst i det underliggende fedmemarked, medfører et løft af vores estimater

Video9/19/2024, 9:38 AM by

Philip Coombes, Claus Thestrup

Gubra: Stærk vækst i det underliggende fedmemarked, medfører et løft af vores estimater

Hvem er Gubra og hvordan vurderer HCA Capital de enkelte forretningsområder.

Gubra

Analyst Comment9/12/2024, 7:03 AM

Dagens aktienyheder 12/09: Gubra og MapsPeople

Dagens aktienyheder med Gubra og MapsPeople

Gubra MapsPeople

Analyst Comment9/10/2024, 7:05 AM

Dagens aktienyheder 10/09: Boozt og Gubra

Dagens aktienyheder med Boozt og Gubra

Boozt Gubra

Gubra (One pager): Obesity Market Upgrade Enhances DCF Estimates

Research9/9/2024, 2:02 PM by

Philip Coombes, Claus Thestrup

Gubra (One pager): Obesity Market Upgrade Enhances DCF Estimates

We have revised our DCF-model, guided by the company, to reflect new estimates for the total obesity market in 2030. With the current share price in line with our latest one-pager from June 2024, the model indicates a lower probability og success (PoS) in the base case.

Gubra

Regulatory press release9/6/2024, 7:42 PM